UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 __________________________________ For the fiscal year ended December 31, 2022 For the transition period from to Delaware 45-3728228 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No x Indicate by c ...

February 2023 Corporate Presentation Transformative genome-edited therapies for patients Forward-looking statements All statements in this presentation, other than statements of historical facts, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements speak only as of the date of this presentation and are subject to a number of known and unknown risks, assumptions, uncertainties, and other factors that may cause the actual ...

Corporate Presentation December 12, 2022 Transformative genome-edited therapies for patients © 2022 Caribou Biosciences, Inc. Forward-looking statements All statements in this presentation, other than statements of historical facts, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forwardlooking statements speak only as of the date of this presentation and are subject to a number of known and unknown risks, assumptions, uncertainties, and othe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 _______________________ ...

Corporate Presentation September 2022 Transformative genome-edited therapies for patients © 2022 Caribou Biosciences, Inc. Forward-looking statements All statements in this presentation, other than statements of historical facts, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forwardlooking statements speak only as of the date of this presentation and are subject to a number of known and unknown risks, assumptions, uncertainties, and other f ...

Corporate Presentation August 2022 Transformative genome-edited therapies for patients © 2022 Caribou Biosciences, Inc. Forward-looking statements All statements in this presentation, other than statements of historical facts, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forwardlooking statements speak only as of the date of this presentation and are subject to a number of known and unknown risks, assumptions, uncertainties, and other fact ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 45-3728228 (State or other jurisdi ...

ANTLER initial clinical data for CB-010 at EHA 2022 June 10, 2022 CB-010 Clinical Program Update – 10 June 2022 1 © 2022 Caribou Biosciences, Inc. Transformative genome-edited therapies for patients Forward-looking statements All statements in this presentation, other than statements of historical facts, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements speak only as of the date of this presentation and are subject to ...

Corporate Presentation June 2022 Corporate Presentation – June 2022 1 © 2022 Caribou Biosciences, Inc. Transformative genome-edited therapies for patients Forward-looking statements All statements in this presentation, other than statements of historical facts, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements speak only as of the date of this presentation and are subject to a number of known and unknown risks, assump ...

Corporate Presentation May 2022 Corporate Presentation – May 2022 1 © 2022 Caribou Biosciences, Inc. Transformative genome-edited therapies for patients Forward-looking statements All statements in this presentation, other than statements of historical facts, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements speak only as of the date of this presentation and are subject to a number of known and unknown risks, assumpti ...